Sanyou Biopharmaceuticals Introduces Clicklinks Platform for Collaborative Drug Discovery

Sanyou Biopharmaceuticals has launched Clicklinks, a new platform described as an innovation hub for original drug discovery, announced in a press release. The platform becomes the third major component within the company’s ecosystem, joining AI-STAL and SAI-DA.

Clicklinks is designed to connect participants across the global pharmaceutical research landscape, including biotech firms, universities, contract research organizations, and investors. It provides a single online portal integrating six core modules that cover the entire drug development process: core reagents, drug discovery, pharmacology and efficacy, innovative technologies, preclinical research, and disease-focused areas such as oncology, neuroscience, and infectious diseases.

The platform supports nearly 70 modular technology systems and covers various therapeutic modalities including antibodies, peptides, nucleic acids, and cell therapies. It aims to streamline collaboration by allowing users to quickly identify partners, technologies, and resources needed for research and development.

Clicklinks builds on the company’s existing AI-STAL and SAI-DA platforms. AI-STAL provides molecular generation capabilities through a large antibody library, while SAI-DA accelerates AI-assisted drug design. Together, the three systems form an integrated network intended to simplify and speed up the creation of new therapeutics.